Cargando…

Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention

INTRODUCTION: The effectiveness of patient education activities conducted within the lenalidomide and thalidomide risk evaluation and mitigation strategies (REMS) programs was evaluated by measuring understanding of serious risk and safe-use messages. METHODS: Results from mandatory knowledge, attit...

Descripción completa

Detalles Bibliográficos
Autores principales: Brandenburg, Nancy A., Bwire, Robert, Freeman, John, Houn, Florence, Sheehan, Paul, Zeldis, Jerome B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362654/
https://www.ncbi.nlm.nih.gov/pubmed/28074423
http://dx.doi.org/10.1007/s40264-016-0501-2
_version_ 1782516994360213504
author Brandenburg, Nancy A.
Bwire, Robert
Freeman, John
Houn, Florence
Sheehan, Paul
Zeldis, Jerome B.
author_facet Brandenburg, Nancy A.
Bwire, Robert
Freeman, John
Houn, Florence
Sheehan, Paul
Zeldis, Jerome B.
author_sort Brandenburg, Nancy A.
collection PubMed
description INTRODUCTION: The effectiveness of patient education activities conducted within the lenalidomide and thalidomide risk evaluation and mitigation strategies (REMS) programs was evaluated by measuring understanding of serious risk and safe-use messages. METHODS: Results from mandatory knowledge, attitude, and behavior surveys and voluntary patient surveys completed between June 2012 and June 2013 were analyzed, and responses to questions relating to compliance with birth control measures and understanding of safe-use messages are presented by patient risk category. RESULTS: In total, 73,645 patients were enrolled into the REMS programs for lenalidomide and thalidomide and completed mandatory surveys prior to medication dispense. Of these, 2790 (3.8%) completed an additional voluntary survey. Among voluntary survey participants, for all patient pregnancy risk categories, reported compliance with birth control requirements was above 90% when starting therapy and at follow-up. At the beginning of therapy, complete compliance was 96.3%; 3 months later it was 96.4%. Patient understanding of safe-use messages was very high in all pregnancy risk groups, notably for messages repeated at each physician visit. Overall, 98.2% of patients knew that lenalidomide and thalidomide could cause birth defects, which is part of the repeated educational messaging. In contrast, 87.1% recalled that unused product should be returned to their healthcare professional, which is not included in repeated messaging. CONCLUSION: The lenalidomide and thalidomide REMS programs enhance patient understanding of safe-use messages, resulting in high levels of compliance with the birth control precautions essential to prevent fetal exposure to these known and potential human teratogens. Overall compliance was maintained after 3 months of follow-up and throughout therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40264-016-0501-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5362654
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-53626542017-04-04 Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention Brandenburg, Nancy A. Bwire, Robert Freeman, John Houn, Florence Sheehan, Paul Zeldis, Jerome B. Drug Saf Original Research Article INTRODUCTION: The effectiveness of patient education activities conducted within the lenalidomide and thalidomide risk evaluation and mitigation strategies (REMS) programs was evaluated by measuring understanding of serious risk and safe-use messages. METHODS: Results from mandatory knowledge, attitude, and behavior surveys and voluntary patient surveys completed between June 2012 and June 2013 were analyzed, and responses to questions relating to compliance with birth control measures and understanding of safe-use messages are presented by patient risk category. RESULTS: In total, 73,645 patients were enrolled into the REMS programs for lenalidomide and thalidomide and completed mandatory surveys prior to medication dispense. Of these, 2790 (3.8%) completed an additional voluntary survey. Among voluntary survey participants, for all patient pregnancy risk categories, reported compliance with birth control requirements was above 90% when starting therapy and at follow-up. At the beginning of therapy, complete compliance was 96.3%; 3 months later it was 96.4%. Patient understanding of safe-use messages was very high in all pregnancy risk groups, notably for messages repeated at each physician visit. Overall, 98.2% of patients knew that lenalidomide and thalidomide could cause birth defects, which is part of the repeated educational messaging. In contrast, 87.1% recalled that unused product should be returned to their healthcare professional, which is not included in repeated messaging. CONCLUSION: The lenalidomide and thalidomide REMS programs enhance patient understanding of safe-use messages, resulting in high levels of compliance with the birth control precautions essential to prevent fetal exposure to these known and potential human teratogens. Overall compliance was maintained after 3 months of follow-up and throughout therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40264-016-0501-2) contains supplementary material, which is available to authorized users. Springer International Publishing 2017-01-10 2017 /pmc/articles/PMC5362654/ /pubmed/28074423 http://dx.doi.org/10.1007/s40264-016-0501-2 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research Article
Brandenburg, Nancy A.
Bwire, Robert
Freeman, John
Houn, Florence
Sheehan, Paul
Zeldis, Jerome B.
Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention
title Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention
title_full Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention
title_fullStr Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention
title_full_unstemmed Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention
title_short Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention
title_sort effectiveness of risk evaluation and mitigation strategies (rems) for lenalidomide and thalidomide: patient comprehension and knowledge retention
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362654/
https://www.ncbi.nlm.nih.gov/pubmed/28074423
http://dx.doi.org/10.1007/s40264-016-0501-2
work_keys_str_mv AT brandenburgnancya effectivenessofriskevaluationandmitigationstrategiesremsforlenalidomideandthalidomidepatientcomprehensionandknowledgeretention
AT bwirerobert effectivenessofriskevaluationandmitigationstrategiesremsforlenalidomideandthalidomidepatientcomprehensionandknowledgeretention
AT freemanjohn effectivenessofriskevaluationandmitigationstrategiesremsforlenalidomideandthalidomidepatientcomprehensionandknowledgeretention
AT hounflorence effectivenessofriskevaluationandmitigationstrategiesremsforlenalidomideandthalidomidepatientcomprehensionandknowledgeretention
AT sheehanpaul effectivenessofriskevaluationandmitigationstrategiesremsforlenalidomideandthalidomidepatientcomprehensionandknowledgeretention
AT zeldisjeromeb effectivenessofriskevaluationandmitigationstrategiesremsforlenalidomideandthalidomidepatientcomprehensionandknowledgeretention